6 treatment settings, 3 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Eradication therapy and endoscopic follow-up; radiotherapy if the lymphoma persists or carries t(11;18).
This setting names no product or technology record yet; the approach above is the standard as written. Ask your team which specific treatments they mean.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.
Add these to your appointment list, or take the full question set for this cancer.
Low-dose involved-site radiotherapy (as little as 4 Gy in two fractions for some sites); surgery rarely.
IMRT and IGRT shape the radiation beam to the tumour's outline from multiple angles and check the patient's position with a scan before every session, so surrounding organs receive less dose. Fewer, larger doses are now standard in breast and prostate cancer, but a low-dose bath still spreads across normal tissue.
Hypofractionation uses larger radiation doses per treatment than a specified comparison schedule, usually with fewer treatments. Control and harms depend on the whole tested regimen.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
Add these to your appointment list, or take the full question set for this cancer.
Watch and wait if asymptomatic; antiviral therapy if hepatitis C-positive; rituximab alone or with chemotherapy; splenectomy now rare.
Rituximab was the first antibody ever approved for cancer (1997). It made chemoimmunotherapy the CLL standard for a decade, and biosimilars keep it cheap and everywhere.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Infusion-related reactions (first infusion) · US label, non-Hodgkin lymphoma studies; falls with each later infusion | 77% | - |
| Late-onset neutropenia (grade 3-4) · US label, previously untreated CLL on rituximab with fludarabine-cyclophosphamide, among 209 patients without prolonged neutropenia; 4.3% with fludarabine-cyclophosphamide alone | 14.8% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Rituximab with bendamustine or chlorambucil, lenalidomide-rituximab; zanubrutinib or ibrutinib for relapsed disease.
Rituximab was the first antibody ever approved for cancer (1997). It made chemoimmunotherapy the CLL standard for a decade, and biosimilars keep it cheap and everywhere.
An East German chemotherapy rediscovered in the 2000s that became the backbone partner for rituximab in follicular, mantle cell and Waldenström lymphomas.
Chlorambucil (Leukeran) is a gentle oral chemotherapy tablet used for decades in chronic lymphocytic leukaemia and low-grade lymphomas, mainly in older patients.
Lenalidomide is a thalidomide descendant that glues the proteins IKZF1 and IKZF3 to cereblon so the cell destroys them, killing plasma cells and rousing T cells. It is the backbone of myeloma treatment and maintenance, also used in mantle cell and follicular lymphoma, and generic since 2022.
Zanubrutinib is the only BTK blocker to beat ibrutinib on progression-free survival in a head-to-head trial, and it caused fewer heart rhythm problems.
The pill that ended chemotherapy for most CLL. It blocks the survival signal B cells depend on, and it was the first drug to beat chemoimmunotherapy in nearly every CLL setting.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Infusion-related reactions (first infusion) · US label, non-Hodgkin lymphoma studies; falls with each later infusion | 77% | - |
| Late-onset neutropenia (grade 3-4) · US label, previously untreated CLL on rituximab with fludarabine-cyclophosphamide, among 209 patients without prolonged neutropenia; 4.3% with fludarabine-cyclophosphamide alone | 14.8% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia · With dexamethasone after at least one prior therapy, the label's two randomised studies, N=353; 3% with placebo and dexamethasone | - | 33% |
| Deep vein thrombosis · With dexamethasone after at least one prior therapy, the label's two randomised studies, N=353; 4% any grade with placebo and dexamethasone | 9% | 8% |
| Haematological second primary malignancy · Maintenance after high-dose melphalan and autologous transplant, the label's two maintenance studies; 3.3% with placebo | 7.5% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutrophils decreased · US label, ALPINE zanubrutinib arm, laboratory grade 3 or 4 | - | 15% |
| Hypertension · US label, ALPINE zanubrutinib arm; 20% with ibrutinib | 19% | 13% |
| Upper respiratory infection · US label, ALPINE zanubrutinib arm | 27% | 1.2% |
| Atrial fibrillation/flutter · US label, ALPINE zanubrutinib arm (relapsed or refractory CLL/SLL, N=324) | 4.6% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Hypertension · US label, 1,476 patients with B-cell malignancies in clinical trials | 19% | 8% |
| Atrial fibrillation and flutter · US label, pooled randomised controlled trials (1,157 patients on ibrutinib, median 19.1 months); 1.6% in the control arms | 8.4% | 4% |
| Diarrhoea · US label, pooled randomised controlled trials; 19% in the control arms | 43% | 3% |
| Arthralgia · US label, RESONATE ibrutinib arm (relapsed CLL/SLL) | 17% | 1% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) arises at a site of chronic inflammation, most often the stomach, and is the one that can sometimes be cured with antibiotics. Splenic marginal zone lymphoma presents with a large spleen, cytopenias and circulating villous lymphocytes, and is associated with hepatitis C. Nodal marginal zone lymphoma behaves much like follicular lymphoma and is treated like it. The three share a cell of origin and very little else in the way of treatment, so the first question is which one it is. Two tests change the plan at diagnosis. Helicobacter pylori status in gastric MALT, because eradication is the first treatment. Hepatitis C status in splenic and nodal disease, because antiviral treatment alone can produce lymphoma remission in hepatitis C-associated cases. Other site-specific associations are recorded and occasionally actionable: Chlamydia psittaci in ocular adnexal MALT, Borrelia burgdorferi in cutaneous MALT, Campylobacter jejuni in immunoproliferative small intestinal disease.
Rituximab was the first antibody ever approved for cancer (1997). It made chemoimmunotherapy the CLL standard for a decade, and biosimilars keep it cheap and everywhere.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Infusion-related reactions (first infusion) · US label, non-Hodgkin lymphoma studies; falls with each later infusion | 77% | - |
| Late-onset neutropenia (grade 3-4) · US label, previously untreated CLL on rituximab with fludarabine-cyclophosphamide, among 209 patients without prolonged neutropenia; 4.3% with fludarabine-cyclophosphamide alone | 14.8% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Treatment is indicated for symptoms, organ compromise, cytopenias or rapid progression, not for the presence of disease. Rituximab alone produces responses in about half. Chemoimmunotherapy with bendamustine and rituximab is the usual choice when more is needed, and rituximab with chlorambucil has randomised evidence in MALT (IELSG-19: five-year event-free survival 68 per cent for the combination against 51 per cent for chlorambucil and 50 per cent for rituximab alone, with five-year overall survival about 90 per cent in each arm, so the combination delays events without changing survival). At relapse, the BTK inhibitors are the newest class: MAGNOLIA treated relapsed or refractory marginal zone lymphoma of all subtypes with zanubrutinib and reported an objective response of 68 per cent, complete response 26 per cent and 15-month progression-free survival of 83 per cent in a single-arm study of 68 patients, two of whom had atrial fibrillation or flutter. Its United States approval for marginal zone lymphoma is still an accelerated one, and ibrutinib's accelerated approval for marginal zone lymphoma was withdrawn on 18 May 2023. Lenalidomide with rituximab is an option and marginal zone patients were included in AUGMENT. Lisocabtagene maraleucel received United States approval for relapsed or refractory marginal zone lymphoma after two or more prior lines on 4 December 2025. Local radiotherapy at 24 Gy remains the right answer for a single symptomatic site whatever the line.
Rituximab was the first antibody ever approved for cancer (1997). It made chemoimmunotherapy the CLL standard for a decade, and biosimilars keep it cheap and everywhere.
An East German chemotherapy rediscovered in the 2000s that became the backbone partner for rituximab in follicular, mantle cell and Waldenström lymphomas.
Chlorambucil (Leukeran) is a gentle oral chemotherapy tablet used for decades in chronic lymphocytic leukaemia and low-grade lymphomas, mainly in older patients.
Zanubrutinib is the only BTK blocker to beat ibrutinib on progression-free survival in a head-to-head trial, and it caused fewer heart rhythm problems.
The pill that ended chemotherapy for most CLL. It blocks the survival signal B cells depend on, and it was the first drug to beat chemoimmunotherapy in nearly every CLL setting.
Lenalidomide is a thalidomide descendant that glues the proteins IKZF1 and IKZF3 to cereblon so the cell destroys them, killing plasma cells and rousing T cells. It is the backbone of myeloma treatment and maintenance, also used in mantle cell and follicular lymphoma, and generic since 2022.
Lisocabtagene maraleucel is the only CAR-T approved for chronic lymphocytic leukaemia, for patients whose disease has outrun both BTK and BCL-2 inhibitors.
Averages across everyone diagnosed, often years ago. A median is the middle of a group: half the people counted lived longer than the figure shown, and some lived far longer. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Infusion-related reactions (first infusion) · US label, non-Hodgkin lymphoma studies; falls with each later infusion | 77% | - |
| Late-onset neutropenia (grade 3-4) · US label, previously untreated CLL on rituximab with fludarabine-cyclophosphamide, among 209 patients without prolonged neutropenia; 4.3% with fludarabine-cyclophosphamide alone | 14.8% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutrophils decreased · US label, ALPINE zanubrutinib arm, laboratory grade 3 or 4 | - | 15% |
| Hypertension · US label, ALPINE zanubrutinib arm; 20% with ibrutinib | 19% | 13% |
| Upper respiratory infection · US label, ALPINE zanubrutinib arm | 27% | 1.2% |
| Atrial fibrillation/flutter · US label, ALPINE zanubrutinib arm (relapsed or refractory CLL/SLL, N=324) | 4.6% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Hypertension · US label, 1,476 patients with B-cell malignancies in clinical trials | 19% | 8% |
| Atrial fibrillation and flutter · US label, pooled randomised controlled trials (1,157 patients on ibrutinib, median 19.1 months); 1.6% in the control arms | 8.4% | 4% |
| Diarrhoea · US label, pooled randomised controlled trials; 19% in the control arms | 43% | 3% |
| Arthralgia · US label, RESONATE ibrutinib arm (relapsed CLL/SLL) | 17% | 1% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia · With dexamethasone after at least one prior therapy, the label's two randomised studies, N=353; 3% with placebo and dexamethasone | - | 33% |
| Deep vein thrombosis · With dexamethasone after at least one prior therapy, the label's two randomised studies, N=353; 4% any grade with placebo and dexamethasone | 9% | 8% |
| Haematological second primary malignancy · Maintenance after high-dose melphalan and autologous transplant, the label's two maintenance studies; 3.3% with placebo | 7.5% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Prolonged cytopenias (grade 3 or higher at day 29) · US label, all lisocabtagene clinical trials across non-Hodgkin lymphomas, not CLL alone | - | 35% |
| Encephalopathy · US label, TRANSCEND CLL 004 (Study 4, N=89) | 44% | 18% |
| Cytokine release syndrome · US label, TRANSCEND CLL 004 (Study 4, relapsed or refractory CLL/SLL, N=89) | 83% | 9% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.